Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

about

Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study

P2860

Q57170878-998108DA-54C1-48D3-9C93-022AFFEE24C3

P2860

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

Item

http://www.wikidata.org/entity/Q39458270

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Impact of abiraterone on patie ...... cancer: current perspectives.

@en

Impact of abiraterone on patie ...... cancer: current perspectives.

@nl

type

Item

label

Impact of abiraterone on patie ...... cancer: current perspectives.

@en

Impact of abiraterone on patie ...... cancer: current perspectives.

@nl

prefLabel

Impact of abiraterone on patie ...... cancer: current perspectives.

@en

Impact of abiraterone on patie ...... cancer: current perspectives.

@nl

P1476

Impact of abiraterone on patie ...... cancer: current perspectives.

@en

P2093

Joelle El-Amm

http://www.w3.org/2001/XMLSchema#string

Rami Nassabein

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

CYP17 inhibitors for prostate cancer therapy

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

P304

299-306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S139305

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jeanny B Aragon-Ching

P577

2017-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28744160

http://www.w3.org/2001/XMLSchema#string

P932

5513839

http://www.w3.org/2001/XMLSchema#string

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

about

P2860

P2860

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932